

Mohammad H Dastjerdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4678631/publications.pdf>

Version: 2024-02-01

29
papers

1,658
citations

516681

16
h-index

642715

23
g-index

29
all docs

29
docs citations

29
times ranked

1577
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab in High-Risk Corneal Transplantation. <i>Ophthalmology</i> , 2022, 129, 865-879.	5.2	6
2	Pterygium recurrence rates in the hispanic population in the Northeastern United States. <i>Journal of Current Ophthalmology</i> , 2021, 33, 298.	0.8	1
3	Corneal Nerve and Epithelial Cell Alterations in Corneal Allodynia: An InÂVivo Confocal Microscopy Case Series. <i>Ocular Surface</i> , 2017, 15, 139-151.	4.4	44
4	A Case of Peripheral Ulcerative Keratitis Associated with Autoimmune Hepatitis. <i>Case Reports in Medicine</i> , 2017, 2017, 1-3.	0.7	5
5	Approach to management of eyes with no light perception after open globe injury. <i>Journal of Ophthalmic and Vision Research</i> , 2016, 11, 313.	1.0	15
6	Quantification of allospecific and nonspecific corneal endothelial cell damage after corneal transplantation. <i>Eye</i> , 2015, 29, 136-144.	2.1	16
7	InÂVivo Confocal Microscopic Changes of the Corneal Epithelium and Stroma in Patients With Herpes Zoster Ophthalmicus. <i>American Journal of Ophthalmology</i> , 2015, 159, 1036-1044.e1.	3.3	16
8	Unilateral Herpes Zoster Ophthalmicus Results in Bilateral Corneal Nerve Alteration. <i>Ophthalmology</i> , 2013, 120, 40-47.	5.2	119
9	Reply. <i>American Journal of Ophthalmology</i> , 2013, 156, 204-205.	3.3	0
10	Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease. <i>JAMA Ophthalmology</i> , 2013, 131, 715.	2.5	99
11	Topical Ranibizumab as a Treatment of Corneal Neovascularization. <i>Cornea</i> , 2013, 32, 992-997.	1.7	76
12	Hyperacute Infectious Keratitis With <i>Plesiomonas shigelloides</i> Following Traumatic Lamellar Corneal Laceration. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1200-1201.	2.0	25
13	Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin). <i>Ocular Surface</i> , 2012, 10, 67-83.	4.4	138
14	Cellular Changes of the Corneal Epithelium and Stroma in Herpes Simplex Keratitis. <i>Ophthalmology</i> , 2012, 119, 1791-1797.	5.2	61
15	Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease. <i>American Journal of Ophthalmology</i> , 2012, 154, 63-71.	3.3	76
16	Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization. <i>American Journal of Ophthalmology</i> , 2012, 154, 940-948.e1.	3.3	44
17	Corneal Penetration of Topical and Subconjunctival Bevacizumab. , 2011, 52, 8718.		111
18	Effect of Topical Azithromycin on Corneal Innate Immune Responses. , 2011, 52, 2525.		35

#	ARTICLE	IF	CITATIONS
19	Corneal graft rejection. , 2010, , 56-63.		2
20	Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant Survival. , 2010, 51, 2411.		79
21	Corneal Sensation and Subbasal Nerve Alterations in Patients with Herpes Simplex Keratitis. Ophthalmology, 2010, 117, 1930-1936.	5.2	252
22	Topical Bevacizumab in the Treatment of Corneal Neovascularization. JAMA Ophthalmology, 2009, 127, 381.	2.4	182
23	High-frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-daily Regimen. Cornea, 2009, 28, 1091-1096.	1.7	86
24	Corneal Nerve Alterations in Dry Eye-associated Ocular Surface Disease. International Ophthalmology Clinics, 2009, 49, 11-20.	0.7	49
25	Shifting-Bubble Sign in Big-Bubble Technique in Deep Anterior Lamellar Keratoplasty. Cornea, 2007, 26, 117.	1.7	7
26	Corneal Decompensation After Laser In Situ Keratomileusis in Fuchs' Endothelial Dystrophy. Cornea, 2003, 22, 379-381.	1.7	37
27	LASEK (laser subepithelial keratomileusis). Current Opinion in Ophthalmology, 2002, 13, 261-263.	2.9	40
28	Customized corneal ablation. Current Opinion in Ophthalmology, 2002, 13, 256-260.	2.9	37
29	Editorial overview: refractive surgery. Current Opinion in Ophthalmology, 2002, 13, 235-236.	2.9	0